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Abstract
Background: The aim of this study was to examine possible differences in clinical outcomes between selective
laser trabeculoplasty (SLT) and topical medication in the treatment of open-angle glaucoma.
Methods: Pertinent prospective comparative controlled trials comparing SLT with medication were selected
through extensive searches of the PubMed, Embase, Web of Science, Chinese Biomedicine Database, and the
Cochrane Controlled Trials Register database from their inception up to March 2014. Efficacy estimates were
measured by their weighted mean difference (WMD) to calculate the intraocular pressure reduction (IOPR) from
baseline to endpoint and by the odds ratio (OR) to determine success rates.
Results: Five prospective studies, which met the predefined criteria, were included in the meta-analysis. Four
studies were randomized clinical trials and one study was a prospective non-randomized clinical trial. There were a
total of 492 eyes of 366 patients with open-angle glaucoma. Four studies involving 325 eyes compared SLT
with medication in terms of the IOPR. The WMD of the IOPR from the baseline was 0.6 (95 % confidence
intervals: −0.24,1.43) when comparing SLT with medication. No statistical heterogeneity was observed between
studies (χ2 = 1.30, P = 0.75, I2 = 0.0 %). All five studies reported success rates, with a pooled OR of 0.84 (95 %
confidence intervals: 0.42, 1.68), which was not statistically significant. No statistical heterogeneity was
observed between studies (χ2 = 5.98, P = 0.200, I2 = 33.1 %). Subgroup and sensitivity analysis confirmed the
high stability of the meta-analysis results.
Conclusions: Both SLT and topical medication demonstrate similar success rates and effectiveness in lowering
intraocular pressure in patients with open-angle glaucoma.
Backgrond
Glaucoma is a leading cause of blindness worldwide [1]. It
is estimated that more than 60 million people had glau-
coma in 2010, 8.4 million of whom are bilaterally blind as
a result of the disease.There are 79.6 million people
around the world who will have glaucoma by 2020, and
74 % of them will have open-angle glaucoma (OAG) [2].
Lowering the intraocular pressure (IOP) is still the goal of
OAG treatment and remains the most effective way to
prevent the development and progression of glaucoma.
Currently, there are three methods available to achieve
this goal: medication, laser treatments, and surgery [3].
Medication therapy is typically the first approach for
reducing IOP. Currently, many kinds of potently
hypotensive topical medicines are available for control-
ling IOP [4]. However, medications have potential disad-
vantages. Patients must tolerate drug side effects,
repeated application of drugs and ongoing medical costs
[5]. The introduction of selective laser trabeculoplasty
(SLT) provided a new non-invasive choice for the
reduction of IOP in eyes with OAG [6]. This treatment
consists of the application of laser spots in the trabecular
meshwork which leads to an increase in the outflow
facility and, consequently, decreases IOP.
In a previous Cochrane systematic review on laser
trabeculoplasty, only one study comparing SLT with
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medication was included, which prevented the meta-
analysis at that time [3]. In a recent meta-analysis compar-
ing SLT with argon laser trabeculoplasty (ALT) in the
treatment of OAG, the role of medication also was not
evaluated [7]. Thus,the effectiveness of SLT compared to
contemporary medication requires further investigation.
Recently, McAlinden et al. [8] reviewed the IOP-lowering
effect when comparing SLT to other glaucoma treatment
options. In that article, the author only described the ef-
fects of SLT and did not perform a meta-analysis.
Currently, several published clinical trials have com-
pared the efficacy and safety of SLT with medical therapy
[9–13]. For example, Lai et al. [13] reported that the IOP-
lowering effect of SLT in Chinese patients is comparable
with topical medications. However, these studies had
modest sample sizes and conveyed inconclusive results.
To date, no consensus has been reached on this topic.
Previously, we conducted a meta-analysis comparing SLT
with ALT; the results reveal that SLT has similar efficacy
to ALT with a similar constellation of side effects [14]. To
our knowledge, the data comparing SLT with topical
medication in the treatment of OAG has not been system-
atically evaluated and reported. Therefore, we conducted a
systematic review and meta-analysis of all published pro-
spective clinical trials to assess the outcomes of SLT versus
medication in the treatment of OAG.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was used as a
guide to conduct the study, including the strategies for
searching, analysis, the presentation of results, poten-
tial bias, interpretation, and writing (Additional file 1:
Table S1) [15].
Literature search and trial selection
Studies were identified and retrieved through a system-
atic search of PubMed, Embase, the Web of Science,
the Chinese Biomedicine Database, and the Cochrane
Controlled Trials Register database from their incep-
tion up to March 2014. Periodical literature update
was performed and the most recent literature retriev-
ing was at June 30, 2015. However, no new original ar-
ticles comparing SLT to medication was identified.
Keywords used in identifying relevant researches in-
cluded ‘selective laser trabeculoplasty’, ‘Yag laser trabe-
culoplasty’, ‘selective laser trabeculectomy’, ‘Nd:YAG’,
‘SLT’, ‘glaucoma’, and ‘ocular hypertension’. Searches
were performed by combining the keywords or their
relevant abbreviations and truncations. No restriction
was applied for language or year of publication. The
websites of professional associations and Google
Scholar were also searched for additional information.
Moreover, a manual search was performed by checking
the reference lists of all retrieved trials to identify studies
not yet included in the computerized databases. Eligible
studies were prospective randomized or non-randomized
comparative controlled trials, which compared the use
of SLT and topical anti-glaucoma medications in adult
patients with any form of naïve OAG or ocular hyper-
tension (OHT).
Data extraction and outcome measures
The information on author, age, sex, country, duration,
sample size, type of glaucoma, study design, and other
outcome data were extracted. The incidence of transient
post-laser IOP spikes, sustained IOP elevation, anterior
chamber reaction, discomfort, redness, and pain were re-
corded. For studies with overlaps of population, the latest
one were included in the final analysis. Given that the ef-
fectiveness of OAG treatment is often assessed by the in-
traocular pressure reduction (IOPR) and percent of
intraocular pressure reduction (IOPR %), the primary effi-
cacy outcomes were the IOPR and IOPR % from the base-
line to the end of follow up. The secondary efficacy
outcome was the success rate. Success was defined as
IOPR ≥ 3 mm Hg and/or IOPR % ≥20 % [7]. The adverse
events in each intervention were also reviewed.
Assessment of methodology quality
The Downs and Blacks scale, which could evaluate both
randomized and non-randomized studies, were used for
assessment of the clinical trials [16]. The system com-
prises 27 items distributed between five subscales regard-
ing reporting (10 items), external validity (three items),
bias (seven items), confounding (six items), and power
(one item). Any discrepancy in the qualitative assessment
between the two observers was discussed and a consensus
was reached. The total score of each trial was expressed
as a percentage of the maximum achievable score.
Studies' methodological quality was assessed as excel-
lent, good, fair, or poor when the total score was ≥20,
from 15 to 19, from 11 to 14, and ≤10, respectively
[17].
Statistical analysis
The intent-to-treat analyses were used in each outcome.
Additionally, data was combined using an inverse variance
random-effects model regardless of heterogeneity
[18].The weighted mean difference (WMD) was calculated
for continuous outcomes while the odds ratio (OR) was
estimated for dichotomous outcomes. All results were
given with 95 % confidence intervals (CIs). Heterogeneity
was checked using Cochran's Q statistic and the P-value.
I2 metrics, which quantify heterogeneity irrespective of
the number of studies, were also reported [19]. Studies
with an I2 value of greater than 50 % were considered
significant heterogeneity. A P-value of less than 0.05
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was considered statistically significant. The statistical
analysis was performed using Stata SE 12.0 (Stata
Corporation LP, College Station, TX, USA).
Sensitivity analysis and publication bias
We also performed subgroup analysis in terms of the
medications used within the medication group. In
addition, we investigated the influence of a single study
on the overall pooled estimate by omitting one study in
each turn. To detect publication biases, we visually ex-
amined asymmetry in funnel plots. Furthermore, the
Begg’s and Egger’s measures were calculated.
Results
Literature search
The initial search yielded 850 relevant publications, of
which 814 were excluded for being duplicates from
multiple databases or for various other reasons (unre-
lated topic,reviews, case reports, or case series) on the
basis of the titles and abstracts. The remaining 30 were
retrieved for full-text review, and 25 of them were ex-
cluded because they were studies comparing SLT with
other laser therapies rather than drugs (Additional file
2: Table S2). Hence, a final total of five studies pub-
lished from 2004–2012 were included in this meta-
analysis [9–13]. Fig. 1 provides a flow diagram of the
search results.
Characteristics and quality assessment of the included
studies
In total, there were 492 eyes from 366 patients included
in this meta-analysis; 318 eyes were included in the SLT
group and 174 eyes were included in the medication
group. The characteristics of the included studies are
summarized in Table 1. The age of patients ranged
Fig. 1 The selection flowchart of clinical trials included in this meta-analysis
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from 25–82 years. One study was a prospective non-
randomized comparative trial [11] and four studies
were randomized clinical trials (RCT) [9, 10, 12, 13].
The studies had the following geographic distribution:
one in the USA, one in China, one in Canada, and two
in the UK. The mean duration of follow-up ranged
from 4–60 months. In the studies included in the
present meta-analysis, SLT was usually performed at
360° with an average power setting between 0.2 mJ and
1.7 mJ. The mean baseline IOP ranged from 25.0 mmHg
to 29.3 mmHg in SLT groups, and from 22.8 mmHg to
29.0 mmHg in medication groups. Our prespecified
definition of success was target IOP, but different and
heterogeneous definitions were used in studies, such as
IOP < 21 mmHg after intervention in one study [13], at
least a 20 % IOP reduction from baseline measurement
in three studies [10–12], and meet the target IOP in
one study [9]. Table 2 shows the quality evaluation of
each clinical trial. The Downs and Blacks score for each
study exceed 16, which indicate adequate methodo-
logical quality.
IOP reduction
Four studies involving 325 eyes compared SLT with
medication in terms of the IOPR (Fig. 2). No statistical
heterogeneity was observed between studies (χ2 = 1.30,
P = 0.75, I2 = 0.0 %). SLT was found to archive a nu-
merically greater IOPR from baseline to end-point;
however, the differences in the IOPR were not all sta-
tistically significant (WMD = 0.6, 95 % CI: −0.24, 1.43)
(Table 3). We divided the studies into 3 subgroups
according medication, and then performed a sensitiv-
ity analysis excluding the non-randomized study.
All subgroups showed that SLT was similar to medi-
cation in IOPR (Table 3). Four studies reported the
IOPR % at follow-up endpoint (Fig. 3). Pooling the re-
sults revealed no significant difference between the
two groups, with a WMD for the IOPR % comparing
SLT with medication of −1.9 % (95 % CI: −5.00 %,
1.10 %) (Table 3). When only including the RCTs, the
differences in IOPR % were also statistically non-
significant (Table 3). Additionally, there was no sig-
nificant heterogeneity in these analyses. Among the
biases in the studies, the unit of analysis issue should
be mentioned because there were 492 eyes of 366
patients, which lead to overestimate precision of effect
estimates since within-patient correlation is not
accounted for.
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controlled trial; Pro = prospective non-RCT; intervention = SLT/medication; BCVA = best corrected visual acuity; C/D = cup to disc ratio; POAG = primary open angle
glaucoma; OHT = ocular hypertension; PDS = pigment dispersion syndrome; PEX = pseudoexfoliation syndrome
Table 2 Quality scoring components for five clinical trials
included in the meta-analysis
Quality score component Score
First Author (year) I II III IV V Over all Percentage (%)
Lai(2004) 11 2 5 3 3 24 75.00 %
Nagar(2005) 11 3 4 3 3 24 71.88 %
McIlraith(2006) 9 2 4 2 2 19 59.38 %
Nagar(2009) 11 3 4 3 3 24 71.88 %
Katz(2012) 11 3 4 3 3 24 71.88 %
I = reporting; II = external validity; III = bias (seven items);
IV = confounding; V = power
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Success rate
Five studies reported the proportions of patients
achieving target endpoint IOP at follow-up endpoint;
the difference in success rate between the SLT group
and the medication group was not statistically signifi-
cant (pooled OR 0.84, 95 % CI: 0.42, 1.68) (Fig. 4). No
statistical heterogeneity was observed between studies
(χ2 = 5.98, P = 0.200, I2 = 33.1 %).For the subgroup, in-
cluding RCTs, the difference in success rate between
the SLT group and the medication group was not statis-
tically significant either (OR 0.85, 95 % CI: 0.34, 2.11).
For the subgroup, including studies using latanoprost,
the difference in success rate was not statistically sig-
nificant (OR 0.57, 95 % CI: 0.23,1.38) (Table 3).
Adverse events
Concerning adverse events, three studies reported the
types and incidences. However, we did not perform a
meta-analysis because there were so few cases.In general,
adverse events were transient and minor. Transient
post-laser IOP spikein some patients was observed.
There were no patients with sustained IOP elevation
Fig. 2 Comparison of intraocular pressure reduction from the baseline between SLT group and topical medication group. WMDs indicate weighted
mean difference, which were computed by using a random-effects model
Table 3 Subgroup analysis of IOP reduction from the baseline and success rate comparing SLT with medication
Group No. of
studies
WMD/OR Test for Heterogeneity Test for Overall Effect
Estimate Lower Up χ2 I2 P Z P
All 4 0.60 −0.24 1.43 1.30 0.00 % 0.730 1.40 0.163
Only RCT 3 0.86 −0.19 1.90 0.65 0.00 % 0.723 1.60 0.110
Combined medication 2 0.64 −0.55 1.83 0.09 0.00 % 0.767 1.05 0.292
Latanoprost-only 2 0.61 −0.73 1.94 1.20 16.4 % 0.274 0.89 0.374
IOPR%
All 4 −1.90 % −5.00 % 1.10 % 3.78 20.50 % 0.287 1.23 0.220
Only RCT 3 −3.20 % −9.10 % 2.70 % 3.77 47.00 % 0.152 1.06 0.290
Combined medication 2 −0.80 % −3.20 % 1.50 % 0.00 0.00 % 0.988 0.67 0.502
Latanoprost-only 2 −5.10 % −13.50 % 3.20 % 2.45 59.2 % 0.117 1.20 0.230
All 5 0.84 0.42 1.68 5.98 33.1 % 0.200 0.50 0.621
Only RCT 4 0.85 0.34 2.11 5.98 49.8 % 0.113 0.35 0.726
Combined medication 2 1.46 0.61 3.49 0.23 0.00 % 0.629 0.85 0.396
Latanoprost-only 3 0.57 0.23 1.38 2.85 29.9 % 0.240 1.26 0.209
IOP = intraocular pressure; SLT = selective laser trabeculoplasty; IOPR = intraocular pressure reduction; IOPR % = percent intraocular pressure reduction from
baseline; Pro = prospective nonrandomized; RCT = prospective randomized controlled trial; OR = odds ratio;
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after SLT. Other common side effects, namely, anterior
chamber reaction, discomfort, redness, and pain were
also described as transient and without sequelae in all
studies.
Sensitivity analysis and publication bias
The sensitivity analyses suggested that each study did
not significantly influence the global estimation of the
IOPR, IOPR %, and success rate (Table 4). Due to the
limited number (<10) of studies included in each ana-
lysis, publication bias was not assessed. Table 5
summarized the overall evidence of SLT versus medicine
in the treatment of OAG.
Discussion
Introduced in 1995 by Park and Latina [20], SLT pro-
vided a new choice for the reduction of IOP in eyes with
OAG. SLT is easy to perform and well tolerated by
patients.However, the efficacy and safety of SLT versus
topical medications for OAG remain unclear. In the pre-
liminary published studies, SLT was used as an adjunct
therapy to medication [21]. Later, several studies
Fig. 3 Comparison of percent intraocular pressure reduction from the baseline between SLT group and topical medication group. WMDs indicate
weighted mean difference, which were computed by using a random-effects model
Fig. 4 Comparison of success rates between SLT group and topical medication group. ORs indicate odds ratios, which were computed by using
a random-effects model
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suggested that SLT may serve as the primary therapy for
OAG [22–26]. Comparisons of SLT and medication were
done in the remaining trials, but there is still not enough
evidence to determine which is the best choice [8].
In this meta-analysis, we reviewed five prospective
comparative controlled trials. The results reveal that
SLT is as effective as medication in regard to the control
of IOP, which is consistent with a previous review [8].
Also, no heterogeneity was observed across the studie-
s.In addition, SLT and medication are similar in their
success rates. The results from our subgroup and sensi-
tivity analyses were quite similar and robust.
The exact mechanisms of SLT lowering IOP are not
known. There are three prevailing theories, namely,
the mechanical theory, the biologic theory, and the
cell theory [27, 28] .According to the mechanical the-
ory, contraction and shrinkage of trabecular beams
caused by SLT exerts a pull on surrounding beams,
which opens up the intertrabecular spaces.The bio-
logic theory proposes that laser energy causes tissue
injury with a resultant cascade of events. Macro-
phages are attracted and alter the secreted extracellu-
lar matrix, allowing an increased aqueous outflow.The
cellular theory suggests that SLT applications stimu-
late cell division in the anterior trabecular meshwork,
providing pluripotent cells for the repopulation of
sites with laser therapy. These cells produce different
extracellular matrices, enhancing the aqueous outflow.
Additionally, there may be other mechanisms of ac-
tion of SLT. It has been reported that exposure to
factors secreted by lasered Schlemm canal cells and
lasered trabecular meshwork cells and the application
of prostaglandin analogs induced junction disassembly
while increasing the permeability of Schlemm canal
cells [29]. Recently, Chen et al. [30] determined the
effect of travoprost (a drug similar to latanoprost) on
Schlemm’s canal in healthy human eyes using fourier-
domain optical coherence tomography. They observed
that travoprost induced the expansion of Schlemm’s
canal lumen. These findings suggest that SLT and
latanoprost might share a common mechanism that
likely mediated their similar IOP lowering effects.
The results of this meta-analysis must be interpreted cau-
tiously in light of the strengths and limitations of the in-
cluded trials. A key strength is the fact that all the studies
included in this meta-analysis were published by established
Table 4 Results of leave-one-out sensitivity analyses
Study
Excluded
Pooled WMD/OR Test for Heterogeneity Test for Overall Effect
Estimate Lower Up χ2 I2 P Z P
IOPR
Lai(2004) 0.62 −0.237 1.48 1.22 0.00 % 0.542 1.42 0.156
McIlraith(2006) 0.86 −0.193 1.90 0.65 0.00 % 0.723 1.60 0.110
Nagar(2009) 0.43 −0.48 1.33 0.37 0.00 % 0.829 0.93 0.353
Katz(2012) 0.51 −0.61 1.64 1.25 0.00 % 0.536 0.89 0.371
IOPR%
Lai(2004) −2.50 % −6.60 % 1.60 % 3.77 46.90 % 0.152 1.18 0.237
McIlraith(2006) −3.20 % −9.10 % 2.70 % 3.77 47.00 % 0.152 1.06 0.290
Nagar(2009) −0.90 % −3.10 % 1.30 % 0.06 0.00 % 0.970 0.83 0.408
Katz(2012) −3.90 % −9.60 % 1.70 % 2.65 24.40 % 0.266 1.37 0.170
Success rate
Lai(2004) 0.68 0.33 1.43 4.02 25.4 % 0.259 1.01 0.311
Nagar(2005) 1.20 0.63 2.29 0.74 0.00 % 0.864 0.54 0.588
McIlraith(2006) 0.85 0.34 2.11 5.98 49.8 % 0.113 0.35 0.726
Nagar(2009) 0.81 0.35 1.87 5.83 48.6 % 0.120 0.50 0.620
Katz(2012) 0.78 0.33 1.85 5.53 45.7 % 0.137 0.57 0.568
CI = confidence interval; IOPR = intraocular pressure reduction; IOPR% = percent intraocular pressure reduction from baseline
Table 5 Summary of finding table of the overall quality of evidence according to GRADE
Outcomes Eye (Study) SLT Med Absolute effect(95 % CI) Relative effect(95 % CI) Quality of evidence Recommend
IOPR 325(4) 190 135 0.60 (−0.24, 1.43) - B Low
IOPR% 325(4) 190 135 −1.90 % (−5.00 %,1.10 %) - B Low
Success rate 298(4) 175 123 0.84 (0.42,1.68) - C Low
Li et al. BMC Ophthalmology  (2015) 15:107 Page 7 of 9
centers of excellence using a prospective comparative con-
trolled design and all of them were well-performed and of
high quality. Despite our rigorous methodology, some limi-
tations of the current study should not be ignored. First, we
cannot fully exclude publication bias. The number of in-
cluded studies is insufficient to carry out statistical testing
to detect publication bias. In addition, we did not attempt
to gain access to unpublished results. Second, our analyses
of IOPR, IOPR %, and success rate were based on data
pooled from trials of different durations. This was due to
the lack of data reported in all phases of follow-up and may
have a potential impact on our results.Third, when discuss-
ing treatment result, it is important to realize that the
criteria used to define success varies between studies.
Differences between studies may also exist with respect
to the diagnostic criteria for glaucoma and the severity
of the disease. Fourth, none of the identified studies
provided a cost-effectiveness analysis; thus, a prospect-
ive randomized clinical trial comparing the cost of SLT
to medication is required. The effectsof SLT on other
outcome measuressuch as delaying the need for surgery
in people with early glaucoma were not assessed. This
may be an interesting focus for future studies.
Conclusions
In conclusion, the present meta-analysis suggests that
SLT appears to be similar to medication in lowering in-
traocular pressures in patients with open angle glau-
coma. Despite our rigorous methodology, the inherent
limitations of the included studies should be considered,
and conclusions drawn from our pooled results should
be interpreted with caution. Future large-volume, well-
designed RCTs with extensive follow-up are awaited to
confirm and update the findings of this analysis.
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